Tuesday, 28. March 2023 | Filed under Company News

InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health

— After promising top-line data for metabolic biomarkers, in-depth data analysis revealed BANON study results not generalizable to HIE patients in clinical routine.

— Development of HypoxE® test based purely on metabolic biomarkers discontinued accordingly.

— Shareholders unanimously approve expansion of business strategy into new areas of pediatric health care.

InfanDx AG, a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health, today announced a strategic repositioning of the Company by broadening its pipeline of innovative solutions for child health.

Read more…

Tuesday, 28. March 2023 | Filed under Company News

Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001

–   Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma

–    First patients to be enrolled in Q2, 2023

Thermosome, a drug development company specializing in targeted tumor therapies, today announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023.

The primary endpoints of the Phase 1, open-label, interventional dose-escalation study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is to evaluate anti-tumor activity. Read more…

Monday, 27. March 2023 | Filed under Company News

HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration

– Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation

HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced positive results of its lead compound HpVac-R13 on airway hyperresponsiveness and inflammation in a murine model of allergic asthma.

Read more…